肝移植术后移植物抗宿主病

doi:10.16139/j.1007-9610.2018.03.003

摘要/Abstract

中图分类号:

R657.3

宫钰, 胡志强, 黄晓武. 肝移植术后移植物抗宿主病[J]. 外科理论与实践, 2018, 23(03): 196-199.

[1] Burdick JF, Vogelsang GB, Smith WJ, et al.Severe graft-versus-host disease in a liver-transplant recipient[J]. N Engl J Med,1988,318(11):689-691.
[2] Murali AR, Chandra S, Stewart Z, et al.Graft versus host disease after liver transplantation in adults: a case series, review of literature, and an approach to management[J]. Transplantation,2016,100(12):2661-2670.
[3] Meng XQ, Chen XH, Sahebally Z, et al.Cytokines are early diagnostic biomarkers of graft-versus-host disease in liver recipients[J]. Hepatobiliary Pancreat Dis Int,2017, 16(1):45-51.
[4] Chen X, Meng X, Xu Y, et al.Cytokine and human leukocyte antigen (HLA) profile for graft-versus-host disease (GVHD) after organ transplantation[J]. Eur J Med Res,2016,21(1):38.
[5] Matsukuma KE, Wei D, Sun K, et al.Diagnosis and differential diagnosis of hepatic graft versus host disease(GVHD)[J]. J Gastrointest Oncol,2016,7(Suppl 1):S21-S31.
[6] Schulz JT 3rd, Sheridan RL. Severe desquamating disorder after liver transplant: toxic epidermal necrolysis or graft versus host disease?[J]. J Burns Wounds,2006,5:e1.
[7] Chaib E, Silva FD, Figueira ER, et al.Graft-versus-host disease after liver transplantation[J]. Clinics (Sao Paulo),2011,66(6):1115-1118.
[8] Schulman JM, Yoon C, Schwarz J, et al.Absence of peripheral blood chimerism in graft-vs-host disease follow-ing orthotopic liver transplantation: case report and review of the literature[J]. Int J Dermatol,2014,53(11):e492-e498.
[9] Akbulut S, Yilmaz M, Yilmaz S.Graft-versus-host disease after liver transplantation: a comprehensive literature review[J]. World J Gastroenterol,2012,18(37):5240-5248.
[10] Mawad R, Hsieh A, Damon L.Graft-versus-host disease presenting with pancytopenia after en bloc multiorgan transplantation: case report and literature review[J]. Transplant Proc,2009,41(10):4431-4433.
[11] Perkins JL, Neglia JP, Ramsay NK, et al.Successful bone marrow transplantation for severe aplastic anemia following orthotopic liver transplantation: long-term follow-up and outcome[J]. Bone Marrow Transplant,2001, 28(5):523-526.
[12] Hudspeth M, Turner A, Miller N, et al.Pancytopenia after allogeneic bone marrow transplant due to copper deficiency[J]. J Pediatr Hematol Oncol,2014,36(4):316-318.
[13] Rogulj IM, Deeg J, Lee SJ.Acute graft versus host disease after orthotopic liver transplantation[J]. J Hematol Oncol,2012,5:50.
[14] Shimata K, Sakamoto R, Anan T, et al.Fatal graft-versus-host disease after living-donor liver transplantation from an HLA-DR-mismatched donor[J]. Pediatr Transplant,2017,21(7).doi: 10.1111/petr.13039.
[15] Uchiyama H, Kayashima H, Matono R, et al.Relevance of HLA compatibility in living donor liver transplantation: the double-edged sword associated with the patient outcome[J]. Clin Transplant,2012,26(5):E522-E529.
[16] Ohe H, Hoshino J, Ozawa M.Factors affecting outcomes of liver transplantation: an analysis of OPTN/UNOS database[J]. Clin Transpl,2011:39-53.
[17] Kamei H, Oike F, Fujimoto Y, et al.Fatal graft-versus-host disease after living donor liver transplantation: differential impact of donor-dominant one-way HLA matching[J]. Liver Transpl,2006, 12(1):140-145.
[18] Elfeki MA, Pungpapong S, Genco PV, et al.Graft-versus-host disease after orthotopic liver transplantation: multivariate analysis of risk factors[J]. Clin Transplant,2015, 29(12):1063-1066.
[19] Zhang C, Yang G, Ling Y, et al.Graft versus host disease following liver transplantation: A case report[J]. Exp Ther Med,2014,8(4):1164-1166.
[20] Chan EY, Larson AM, Gernsheimer TB, et al.Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients[J]. Liver Transpl,2007,13(4):516-522.
[21] Rai V, Dietz NE, Agrawal DK.Immunological basis for treatment of graft versus host disease after liver transplant[J]. Expert Rev Clin Immunol,2016,12(5):583-593.
[22] Jeanmonod P, Hubbuch M, Grunhage F, et al.Graft-versus-host disease or toxic epidermal necrolysis: diagnostic dilemma after liver transplantation[J]. Transpl Infect Dis,2012,14(4):422-426.
[23] Grosskreutz C, Gudzowaty O, Shi P, et al.Partial HLA matching and RH incompatibility resulting in graft versus host reaction and Evans syndrome after liver transplantation[J]. Am J Hematol,2008,83(7):599-601.
[24] Mousavi SA, Javadimoghadam M, Ghavamzadeh A, et al.The relationship between STR-PCR chimerism analysis and chronic GvHD following hematopoietic stem cell transplantation[J]. Int J Hematol Oncol Stem Cell Res,2017,11(1):24-29.
[25] Soejima Y, Shimada M, Suehiro T, et al.Graft-versus-host disease following living donor liver transplantation[J]. Liver Transpl,2004,10(3):460-464.
[26] Kuball J, Theobald M, Ferreira EA, et al.Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions[J]. Transplantation,2004,78(12):1774-1779.
[27] Thin L, Macquillan G, Adams L, et al.Acute graft-versus-host disease after liver transplant: novel use of eta-nercept and the role of tumor necrosis factor alpha inhibitors[J]. Liver Transpl,2009,15(4):421-426.
[28] Piton G, Larosa F, Minello A, et al.Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report[J]. Liver Transpl,2009,15(7):682-685.
[29] Trounson A, Thakar RG, Lomax G, et al.Clinical trials for stem cell therapies[J]. BMC Med,2011,9:52.
[30] Chen W, Li M, Li Z, et al.CXCR4-transduced me-senchymal stem cells protect mice against graft-versus-host disease[J]. Immunol Lett,2012,143(2):161-169.
[31] Ringdén O, Erkers T, Nava S, et al.Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease[J]. Stem Cells,2013,31(3):592-601.

肝移植术后移植物抗宿主病

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨雪, 刘锦, 王铮, 陶杰, 郝杰, 李宇, 孙昊. 他克莫司降低肝移植病人ERCP术后胰腺炎发生的临床观察[J]. 外科理论与实践, 2022, 27(3): 253-255.
[2]	吴浩翔, 吕子成, 侯宇宸, 张子杰, 乔子耘, 冯浩, 夏强. 儿童肝移植中他克莫司浓度个体内变异[J]. 外科理论与实践, 2022, 27(02): 145-151.
[3]	张磊, 毛家玺, 李涛, 滕飞, 孙克彦. 术前免疫炎症反应对原发性胆汁性胆管炎肝移植病人预后影响的双中心回顾性研究[J]. 外科理论与实践, 2022, 27(02): 158-164.
[4]	黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.
[5]	冯浩, 吕子成, 夏强. 肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022, 27(02): 119-122.
[6]	李涛, 陈皓. 肝硬化门静脉高压症的肝移植治疗[J]. 外科理论与实践, 2021, 26(03): 189-194.
[7]	戚德彬, 陈鹏, 佟辉, 彭承宏, 李涛. 肝移植术后撤除免疫抑制剂的回顾性分析[J]. 外科理论与实践, 2021, 26(03): 231-235.
[8]	黄成, 孙惠川. 《原发性肝癌诊疗规范（2019年版）》肝脏外科领域更新的展望[J]. 外科理论与实践, 2020, 25(01): 6-9.
[9]	佟辉, 陈鹏, 张家强, 谢俊杰, 李涛, 祝哲诚, 彭承宏. 加速康复外科在肝癌肝移植中的临床应用[J]. 外科理论与实践, 2020, 25(01): 45-49.
[10]	滕飞, 傅志仁. 基于门静脉重建方案的肝移植围术期门静脉血栓处理策略[J]. 外科理论与实践, 2018, 23(03): 191-195.
[11]	佟辉, 张家强, 祝哲诚, 彭承宏, 李涛. 超“UCSF标准”肝细胞癌肝移植术前经肝动脉化疗栓塞的疗效[J]. 外科理论与实践, 2018, 23(03): 241-246.
[12]	李涛, 祝哲诚, 彭承宏. 肝移植“精准”治疗原发性肝脏恶性肿瘤[J]. 外科理论与实践, 2018, 23(03): 200-204.
[13]	马彦, 臧爱萍, 杨焕凤, 侯健,. 间充质干细胞在治疗移植物抗宿主病中的应用[J]. 内科理论与实践, 2018, 13(02): 124-128.
[14]	赵莉敏, 陆莹婷, 王苓, 蒋雪玮, 翟元梅, 杨莉, 侯海珠, 胡炯, 刘立根,. 亲缘半相合外周血造血干细胞移植后胰腺急性移植物抗宿主病1例[J]. 内科理论与实践, 2018, 13(02): 113-114.
[15]	刘慧霞, 邵珊, 姜杰玲, 杨隽, 万理萍, 白海涛, 李肃, 王椿, 宋献民,. 去除第11天甲氨蝶呤方案预防同胞相合供体造血干细胞移植后急性移植物抗宿主病[J]. 内科理论与实践, 2018, 13(02): 87-91.